Apricus Biosciences, Inc. (APRI) was a big mover last session, as the company saw its shares rise almost 19% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This reverses the recent trend for the company, as the stock is now down more than 9% in the past one-month time frame.
The company has seen one positive and one negative estimate revision in the past 30 days, while its Zacks Consensus Estimate moved lower over the same time frame, suggesting trouble down the road. So make sure to keep an eye on this stock going forward to see if this recent move higher can last.
Apricus Biosciences currently has a Zacks Rank #3 (Hold) while its Earnings ESP is 0.00%.
Some better-ranked medical stocks include Grifols, S.A. (GRFS), ImmunoGen, Inc. (IMGN) and Enanta Pharmaceuticals, Inc. (ENTA). All these stocks sport a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
APRICUS BIOSCIENCES INC (APRI): Free Stock Analysis Report
GRIFOLS SA ADS (GRFS): Free Stock Analysis Report
IMMUNOGEN INC (IMGN): Free Stock Analysis Report
ENANTA PHARMACEUTICALS INC (ENTA): Free Stock Analysis Report
Zacks Investment Research
- Finance Trading
- Personal Investing Ideas & Strategies
- Apricus Biosciences